ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodentsUnderstanding the pharmacogenetics of selective serotonin reuptake inhibitors.Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: a pilot study.Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han populationImproved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report.Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients.Mechanisms of antidepressant resistanceHigh impact child abuse may predict risk of elevated suicidality during antidepressant initiation.Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy.Tools for studying drug transport and metabolism in the brain.Systems biology approaches to adverse drug effects: the example of cardio-oncology.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis.Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder.ABCB1 genotyping in the treatment of depression.Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study.ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort.ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway.Nanomedicine applications in women's health: state of the art.
P2860
Q26741187-A73545C7-A578-40A0-B5D9-B37A62D26DEFQ26996411-FE82BDF7-1626-44BA-9415-7B1C4AEC6637Q30544869-6743CC88-BC7D-4A5A-A6FD-BF27BC2DC23BQ34424865-B7DA4C19-3C18-4C5F-8CAB-DC57840FF7F8Q35579226-C080CE58-855F-4077-933B-79E347B2A73FQ35934911-DE4E9024-B303-4D71-823F-9E6496D038D5Q35965584-1D63F33A-65A4-471F-8880-969CC2331E52Q36323164-8B742839-DD4A-4ACD-B223-4F4F2F4A4696Q36325439-ED84BD88-ABB0-47E0-A4A8-43566C2048ACQ37334088-8F4AAF3E-3E6C-4FCB-93C9-F0D57CCD8C49Q38166559-45A64797-C5B0-4625-8AAB-90FE7ED93F35Q38440275-23683A2E-794C-463B-9AC1-9184F3C75DC1Q38560853-8F4762EC-729A-4AD1-982A-C420DA0197B8Q38606067-F12B304F-430D-40C1-9E23-A44D66DE4619Q38983579-B907EB9C-0F9B-4207-BFCA-EFBE3E8ACC5BQ39021015-8BBC53DB-7578-4307-A54E-3CABFAF30C84Q39025173-C52B3464-CD28-4167-BAF7-9EA2CB73C6B6Q39029387-B9811B19-DA48-447D-973A-6B1443888923Q39113007-86E317A0-80FB-4FF7-8FF8-88067B9BBE4FQ40149970-E2E878A7-6A68-45B0-B3C9-9CA7F70008DBQ42130578-421CCFEF-BFD0-477F-B6E7-94C9F05F9BEBQ48156013-7ACC2689-67C0-4190-800D-864167598DA3Q48170776-2C5DECF7-B66F-4810-8108-1920E9A73166Q48468840-2787D9E1-ACEF-459C-ABE4-18876C01D031Q55091399-95DD1379-1800-483E-B783-3BF97D0258D2
P2860
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@ast
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@en
type
label
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@ast
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@en
prefLabel
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@ast
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@en
P2093
P2860
P356
P1476
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
@en
P2093
P2860
P2888
P356
10.1038/TP.2012.115
P577
2012-11-27T00:00:00Z